YHYirui Hu

Yirui Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yirui Hu has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improvements in Albuminuria Screening Among Individuals with Hypertension Associated with Electronic Health Record Clinical Decision Support Design Changes

    by Waleed Zafar, Spencer Tavares, Yirui Hu, Lauren Brubaker, Jamie Green, Sneha Mehta, Morgan E. Grams, Alexander R. Chang

    Background: Albuminuria is associated with increased risk of cardiovascular disease (CVD), heart failure, and progression of chronic kidney disease (CKD). Early detection of albuminuria, done through spot urine albumin creatinine ratio (UACR) testing, enables more accurate risk stratification and timely use of preventative therapies. It remains unacceptably low in the hypertension population. Methods: We evaluated two EHR-embedded clinical decision support (CDS) strategies at Geisinger Health System in order to increase UACR testing in individuals with hypertension: an OurPractice Advisory (OPA) from Jan 2022 to Aug 2022; and a Health Maintenance Topic (HMT) in the Care Gaps section of Storyboard from Aug 2022 that continues to date. We evaluated UACR rates from 2020 to 2023 in Geisinger primary care and compared to a control group of healthcare systems in the Optum Labs Data Warehouse [OLDW]. Patients were excluded if they had UACR testing in the preceding 3 years, had diabetes or CKD, or were receiving palliative/hospice care. Results: We included 58,876 individuals in Geisinger (mean age 59.4 years, 49.6% female) and 1,427,754 in OLDW (61.0 years, 49% female). UACR testing in Geisinger (2.97% in 2020; 2.8% in 2021; 9.7% in 2022; 17.5% in 2023) showed significant increase compared to the control health systems (2.08%, 2.26%, 3.35% and 3.40% respectively). Results were consistent after adjusting for age, sex and race. Conclusion: OPA increased UACR testing ∼3-fold whereas the HMT was associated with further improvements (∼6-fold vs. baseline) among those with hypertension, suggesting an important role for CDS design in closing care gaps.

  • Open Access

    Examining Referral Pathways for Patients with Hematuria: A Real-World Retrospective Analysis

    by Alexander R. Chang, Yirui Hu, Lauren Brubaker, Jamie Green, Waleed Zafar, Briana Ndife, Carolina Aldworth

    Introduction: Follow-up for hematuria, often found incidentally on urinalysis, is critical as it may be an early sign of glomerular disease or malignancy. We evaluated nephrology and urology referral patterns for outpatients with hematuria, and factors associated with nephrology and urology referrals. Methods: This retrospective, observational cohort study leveraged electronic health record data from a large, regional health care system in Pennsylvania, USA. Outpatients with hematuria (≥1+ blood) on dipstick urinalysis from January 1, 2022, to September 30, 2022, without nephrology/urology appointments in the prior 10 years or prior genitourinary cancer were enrolled. The primary objective evaluated the proportion of outpatients with hematuria who had nephrology or urology referrals or appointments within 6 months following initial presentation. Secondary objectives evaluated concurrent proteinuria and follow-up testing patterns. Results: The mean (standard deviation) age of the 5,475 outpatients with hematuria on urinalysis was 60.5 (20.8) years, and most were female (78.0%). Overall, 774/5,475 (14.1%) patients with hematuria had a nephrology or urology referral/appointment within 6 months following presentation. Urine microscopy was performed at the time of hematuria detection for 3,324/5,475 (60.7%) patients, of whom 2,388 (71.8%) had ≥3 red blood cells (RBCs) per high-power field (HPF). Repeat urinalysis was performed for 1,582/5,475 (28.9%) patients. Increased referral likelihood was associated with male sex (odds ratio: 2.3; 95% confidence interval [CI]: 1.9–2.7) and ≥30 RBCs/HPF on microscopy (odds ratio: 1.7; 95% CI: 1.3–2.1). Of 4,952 patients with proteinuria data, 2,375 (48.0%) had hematuria and ≥1+ protein on urinalysis, and 373/2,375 (15.7%) had nephrology (n = 58; 2.4%) and/or urology (n = 332; 14.0%) referrals within 6 months. Conclusion: This study provides insight into current outpatient hematuria management patterns. The low referral rates, particularly with concurrent hematuria and proteinuria, highlight opportunities to improve management moving forward.

  • Outcomes following use of IPACK nerve block: A systematic review and meta-analysis of randomized controlled trials

    by Frank Vazquez, Emily Ellison, Adam Cole, Yirui Hu, Yagiz Ozdag, Jeffrey M. Gillette, John J. Mercuri


  • Open Access

    Development and multi-site external validation of a generalizable risk prediction model for bipolar disorder

    by Colin G. Walsh, Michael A. Ripperger, Yirui Hu, Yi-Han Sheu, Hyunjoon Lee, Drew Wilimitis, Amanda B. Zheutlin, Daniel Rocha, Karmel W. Choi, Victor M. Castro, et al.

    Bipolar disorder is a leading contributor to disability, premature mortality, and suicide. Early identification of risk for bipolar disorder using generalizable predictive models trained on diverse cohorts around the United States could improve targeted assessment of high risk individuals, reduce misdiagnosis, and improve the allocation of limited mental health resources. This observational case-control study intended to develop and validate generalizable predictive models of bipolar disorder as part of the multisite, multinational PsycheMERGE Network across diverse and large biobanks with linked electronic health records (EHRs) from three academic medical centers: in the Northeast (Massachusetts General Brigham), the Mid-Atlantic (Geisinger) and the Mid-South (Vanderbilt University Medical Center). Predictive models were developed and valid with multiple algorithms at each study site: random forests, gradient boosting machines, penalized regression, including stacked ensemble learning algorithms combining them. Predictors were limited to widely available EHR-based features agnostic to a common data model including demographics, diagnostic codes, and medications. The main study outcome was bipolar disorder diagnosis as defined by the International Cohort Collection for Bipolar Disorder, 2015. In total, the study included records for 3,529,569 patients including 12,533 cases (0.3%) of bipolar disorder. After internal and external validation, algorithms demonstrated optimal performance in their respective development sites. The stacked ensemble achieved the best combination of overall discrimination (AUC = 0.82–0.87) and calibration performance with positive predictive values above 5% in the highest risk quantiles at all three study sites. In conclusion, generalizable predictive models of risk for bipolar disorder can be feasibly developed across diverse sites to enable precision medicine. Comparison of a range of machine learning methods indicated that an ensemble approach provides the best performance overall but required local retraining. These models will be disseminated via the PsycheMERGE Network website.


  • Open Access

    479. Performance Differences in Electronic Health Record Algorithm for Bipolar Disorder by Race and Ethnicity: An Assessment From the Psychemerge Diversity Initiative

    by Roseann Peterson, Rachel Kember, Tian Ge, Laura Huckins, Georgios Voloudakis, Rebecca Birnbaum, Yirui Hu, Hyunjoon Lee, Daniel Rocha, Simone Tomasi, et al.

  • Open Access

    P068: Feasibility and initial participation in traceback cascade screening programs for ovarian cancer implemented at three integrated health systems

    by Tracey Leitzel, Alanna Kulchak Rahm, Saumya Patel, Rachel Schwiter, Meredith Lewis, Yirui Hu, M. Cabell Jonas, Pim Suwannarat, Adrienne Deneal, Sundeep Basra, et al.

  • Identifying High-Risk Comorbidities Associated with Opioid Use Patterns Using Electronic Health Record Prescription Data

    by Mariela V. Jennings, Hyunjoon Lee, Daniel B. Rocha, Sevim B. Bianchi, Brandon J. Coombes, Richard C. Crist, Annika B. Faucon, Yirui Hu, Rachel L. Kember, Travis T. Mallard, et al.

    Introduction: Opioid use disorders (OUDs) constitute a major public health issue, and we urgently need alternative methods for characterizing risk for OUD. Electronic health records (EHRs) are useful tools for understanding complex medical phenotypes but have been underutilized for OUD because of challenges related to underdiagnosis, binary diagnostic frameworks, and minimally characterized reference groups. As a first step in addressing these challenges, a new paradigm is warranted that characterizes risk for opioid prescription misuse on a continuous scale of severity, i.e., as a continuum. Methods: Across sites within the PsycheMERGE network, we extracted prescription opioid data and diagnoses that co-occur with OUD (including psychiatric and substance use disorders, pain-related diagnoses, HIV, and hepatitis C) for over 2.6 million patients across three health registries (Vanderbilt University Medical Center, Mass General Brigham, Geisinger) between 2005 and 2018. We defined three groups based on levels of opioid exposure: no prescriptions, minimal exposure, and chronic exposure and then compared the comorbidity profiles of these groups to the full registries and to those with OUD diagnostic codes. Results: Our results confirm that EHR data reflects known higher prevalence of substance use disorders, psychiatric disorders, medical, and pain diagnoses in patients with OUD diagnoses and chronic opioid use. Comorbidity profiles that distinguish opioid exposure are strikingly consistent across large health systems, indicating the phenotypes described in this new quantitative framework are robust to health systems differences. Conclusion: This work indicates that EHR prescription opioid data can serve as a platform to characterize complex risk markers for OUD using existing data.


  • Open Access

    Evaluation of a Web-Based Medication Reconciliation Application Within a Primary Care Setting: Cluster-Randomized Controlled Trial

    by Michael R Gionfriddo, Yirui Hu, Bhumika Maddineni, Melissa Kern, Vanessa Hayduk, William R Kaledas, Nevan Elder, Jeffrey Border, Katie Frusciante, Maria Kobylinski, et al.

    Background: Despite routine review of medication lists during patient encounters, patients’ medication lists are often incomplete and not reflective of actual medication use. Contributing to this situation is the challenge of reconciling medication information from existing health records, along with external locations (eg, pharmacies, other provider/hospital records, and care facilities) and patient-reported use. Advances in the interoperability and digital collection of information provides a foundation for integration of these once disparate information sources. Objective: We aim to evaluate the effectiveness of and satisfaction with an electronic health record (EHR)-integrated web-based medication reconciliation application, MedTrue (MT). Methods: We conducted a cluster-randomized controlled trial of MT in 6 primary care clinics within an integrated health care delivery system. Our primary outcome was medication list accuracy, as determined by a pharmacist-collected best-possible medication history (BPMH). Patient and staff perspectives were evaluated through surveys and semistructured interviews. Results: Overall, 224 patients were recruited and underwent a BPMH with the pharmacist (n=118 [52.7%] usual care [UC], n=106 [47.3%] MT). For our primary outcome of medication list accuracy, 8 (7.5%) patients in the MT arm and 9 (7.6%) in the UC arm had 0 discrepancies (odds ratio=1.01, 95% CI 0.38-2.72, P=.98). The most common discrepancy identified was patients reporting no longer taking a medication (UC mean 2.48 vs MT mean 2.58, P=.21). Patients found MT easy to use and on average would highly recommend MT (average net promoter score=8/10). Staff found MT beneficial but difficult to implement. Conclusions: The use of a web-based application integrated into the EHR which combines EHR, patient-reported data, and pharmacy-dispensed data did not improve medication list accuracy among a population of primary care patients compared to UC but was well received by patients. Future studies should address the limitations of the current application and assess whether improved implementation strategies would impact the effectiveness of the application.


  • Circ_0003611 acts as a miR-885-5p sponge to aggravate the amyloid-β-induced neuronal injury in Alzheimer’s disease

    by Weihua Pan, Yirui Hu, Lihong Wang, Jing Li

    Alzheimer’s disease (AD) is a chronic degenerative disease in the central nervous system and circular RNAs (circRNAs) are identified as essential regulators in AD. The current research was designed for exploration of circ_0003611 in AD. Circ_0003611 was overexpressed in AD patients and Aβ-treated SK-N-SH cells. Aβ-induced apoptotic, inflammatory and oxidative damages were relieved after knockdown of circ_0003611. MiR-885-5p was validated as a miRNA target of circ_0003611. The protective function of circ_0003611 downregulation was achieved by releasing miR-885-5p in Aβ-treated SK-N-SH cells. KREMEN1 was a downstream gene of miR-885-5p. Overexpression of miR-885-5p attenuated the Aβ-triggered cell injury by reducing the KREMEN1 expression. KREMEN1 was regulated by circ_0003611 via sponging miR-885-5p in Aβ-treated SK-N-SH cells. These experimental data demonstrated that circ_0003611 enhanced the Aβ-induced neuronal cell injury in AD by serving as the miR-885-5p sponge to regulate the level of KREMEN1.


  • Open Access

    Evaluation of a Web-Based Medication Reconciliation Application Within a Primary Care Setting: Cluster-Randomized Controlled Trial (Preprint)

    by Michael R Gionfriddo, Yirui Hu, Bhumika Maddineni, Melissa Kern, Vanessa Hayduk, William R Kaledas, Nevan Elder, Jeffrey Border, Katie Frusciante, Maria Kobylinski, et al.

    BACKGROUND Despite routine review of medication lists during patient encounters, patients’ medication lists are often incomplete and not reflective of actual medication use. Contributing to this situation is the challenge of reconciling medication information from existing health records, along with external locations (eg, pharmacies, other provider/hospital records, and care facilities) and patient-reported use. Advances in the interoperability and digital collection of information provides a foundation for integration of these once disparate information sources. OBJECTIVE We aim to evaluate the effectiveness of and satisfaction with an electronic health record (EHR)-integrated web-based medication reconciliation application, MedTrue (MT). METHODS We conducted a cluster-randomized controlled trial of MT in 6 primary care clinics within an integrated health care delivery system. Our primary outcome was medication list accuracy, as determined by a pharmacist-collected best-possible medication history (BPMH). Patient and staff perspectives were evaluated through surveys and semistructured interviews. RESULTS Overall, 224 patients were recruited and underwent a BPMH with the pharmacist (n=118 [52.7%] usual care [UC], n=106 [47.3%] MT). For our primary outcome of medication list accuracy, 8 (7.5%) patients in the MT arm and 9 (7.6%) in the UC arm had 0 discrepancies (odds ratio=1.01, 95% CI 0.38-2.72, P=.98). The most common discrepancy identified was patients reporting no longer taking a medication (UC mean 2.48 vs MT mean 2.58, P=.21). Patients found MT easy to use and on average would highly recommend MT (average net promoter score=8/10). Staff found MT beneficial but difficult to implement. CONCLUSIONS The use of a web-based application integrated into the EHR which combines EHR, patient-reported data, and pharmacy-dispensed data did not improve medication list accuracy among a population of primary care patients compared to UC but was well received by patients. Future studies should address the limitations of the current application and assess whether improved implementation strategies would impact the effectiveness of the application.